Tech Company Financing Transactions
Avidia Funding Round
On 5/9/2006, Avidia raised $43.8 million in Series C funding from Skyline Ventures, Alloy Ventures and Amgen Ventures.
Transaction Overview
Company Name
Announced On
5/9/2006
Transaction Type
Venture Equity
Amount
$43,800,000
Round
Series C
Investors
Skyline Ventures (Lead Investor) (David Lowe)
HealthCare Ventures (Harold Werner)
Proceeds Purpose
The Company expects to use the proceeds to continue to advance the development of its lead products, which include an inhibitor of interleukin 6 for the treatment of inflammation and autoimmune disease, scheduled to enter clinical trials this year, and an inhibitor of IgE, on track to enter clinical trials next year. Proceeds will also be used to further expand Avidia's product portfolio and to support the continued exploration of unique Avimer Protein applications.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
2450 Bayshore Pkwy. 200
Mountain View, CA 94043
USA
Mountain View, CA 94043
USA
Phone
Website
Email Address
Not Recorded
Overview
Avidia, a biopharmaceuticals company founded in 2003, is committed to developing medicines for patients with serious unmet medical conditions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 5/9/2006: Auvitek International venture capital transaction
Next: 5/9/2006: Incentive Logic venture capital transaction
Share this article
Where The Data Comes From
We do our best to record funding rounds that are announced publicly. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs